Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Assess which retirement index fund offers the best expense ratio, balancing cost with diversification and tracking accuracy.
28,154 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Looking for growth you can ride for years? This guide breaks down three powerhouse names—NVIDIA, Microsoft, and Alpha...
A major fund stepped in with a bold $30 million wager on Floor & Decor after a sharp 30% decline. This article breaks...
A little-known income ETF has doubled this year by selling covered calls on AMD, outperforming the broad market as th...
VanEck BDC Income ETF faces pressure from rate cuts eating into floating-rate loan income. Distributions declined in ...
A discreet fund quietly builds a Mattel stake, signaling conviction or a calculated thesis. This article breaks down ...
WNC & Associates closed a $210 million LIHTC fund to finance 18 affordable housing communities across 13 states, deli...
A deceitful ‘psychic’ preyed on grief and financial stress, turning trust into theft. Learn the warning signs, practi...
This in-depth guide breaks down what to watch in Ziff Davis's Q1 2026 earnings transcript, how growth drivers shape t...
Broadcom has faced a stock pullback even as AI-driven revenue climbs. This article digs into the reasons behind the d...
Long-term investing isn’t about chasing the hottest trend. It’s about finding durable brands that can pay and grow di...
A niche nuclear tech stock reported solid revenue gains, but a large fund reduced its holdings. Learn how to read the...